证券代码：688443 证券简称：智翔金泰 公告编号：2025-027 重庆智翔金泰生物制药股份有限公司 本次回购股份符合法律法规的规定及公司回购股份方案。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/16 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 15 日~2025 10 | 10 | 月 | 年 | 月 | 14 | 日 | | 预计回购金额 | 2,000万元~4,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 796,100股 | | | | | | | | 累计已回购股数占总股本比例 | 0.2171% | | | | | | | | 累计 ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company has successfully entered the global market with its product GR1803 through a licensing agreement with Cullinan Therapeutics, which includes a total milestone payment of up to $712 million [1] - The company is rapidly expanding its domestic and international business lines, with significant clinical trial progress and new drug applications [2] - The leading product, Celeric monoclonal antibody, is expected to launch in August 2024 and participate in medical insurance negotiations in 2025 [2] Financial Projections - Revenue projections for 2025-2027 are estimated at 206 million, 500 million, and 1.078 billion yuan respectively, with net losses expected to decrease from 622 million to 275 million yuan over the same period [2][4] - The company anticipates a significant year-on-year revenue growth rate of 2,384.1% in 2024 and 584.5% in 2025 [4] - The latest diluted EPS is projected to improve from -2.19 yuan in 2023 to -0.75 yuan in 2027 [4] Business Development - The company has submitted a new drug application for GR2001, which has reached the primary efficacy endpoint in its Phase III clinical trial for tetanus passive immunity [2] - The collaboration with Cullinan Therapeutics focuses on the CD3/BCMA target, indicating a strategic enhancement in the company's autoimmune TCE dual antibody layout [1]

智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为329,140.14 万元。智翔金泰实际募资净额比原拟募集资金金额少68,859.86万元。智翔金泰于2023年6月15日披露的 招股说明书显示，该公司拟募集资金398,000.00万元，用于抗体产业化基地项目一期改扩建、抗体产业 化基地项目二期、抗体药物研发项目、补充流动资金。 智翔金泰首次公开发行股票的发行费用合计18,143.70万元(不含税)，其中，保荐承销费16,495.98万元。 2020年至2024年，公司营业收入分别为108.77万元、3,919.02万元、47.52万元、121.15万元、3,009.50万 元，归属于上市公司股东的净利润分别为-37,261.56万元、-32,213.27万元、-57,636.57万元、-80,131.93 万元、-79,727.36万元，归属于上市公司股东的扣除非经常性损益的净利润分别为-14,155.53万 元、-33,387.33万元、-64,536.25万元、-81,292.85万元、-80,432.96万元，经营活动产生的现金流量净额 分别为-14,039. ...

Core Viewpoint - The company has made significant changes in its fundamentals since its listing two years ago, highlighted by a licensing agreement with Cullinan Therapeutics for the GR1803 dual antibody, which could yield over $712 million in total payments and revenue sharing [1][2][3]. Group 1: Licensing Agreement and Financial Implications - The licensing agreement with Cullinan Therapeutics grants them global rights for GR1803 outside of China, while the company retains rights within China [2][3]. - The agreement includes an upfront payment of $20 million and potential milestone payments of up to $692 million, along with revenue sharing, totaling over $712 million [1][3]. - The GR1803 injection is currently in Phase II clinical trials and is aimed at treating relapsed/refractory multiple myeloma, with promising early clinical data showing an overall response rate of 85% [3]. Group 2: Product Commercialization and Market Challenges - The company’s first commercialized product, Selecitinib (IL-17A monoclonal antibody), achieved sales of 30 million yuan after receiving approval for psoriasis treatment, but missed the opportunity for insurance reimbursement negotiations [1][6]. - The company reported a significant revenue increase of 2384.1% year-on-year, reaching 30.09 million yuan, but still faced a net loss of 797 million yuan [6]. - The company is actively working to negotiate for Selecitinib's inclusion in the insurance reimbursement list to enhance market penetration and sales volume [6][7]. Group 3: Future Strategies and Market Environment - The company plans to adopt a dual strategy for future growth, utilizing a sales outsourcing model domestically while pursuing early licensing agreements internationally [4]. - The innovative drug market is experiencing favorable conditions, with a surge in business development activities, as evidenced by a total of $45.5 billion in domestic innovative drug business development in the first five months of 2025 [4][7]. - The company anticipates that profitability may not be achieved until 2027, despite plans for two additional product launches in the future [7].

北京市万商天勤律师事务所 关于重庆智翔金泰生物制药股份有限公司 2024 年年度股东大会的 法律意见书 1 北京市万商天勤律师事务所 关于重庆智翔金泰生物制药股份有限公司 2024 年年度股东大会的 法律意见书 致：重庆智翔金泰生物制药股份有限公司 北京市万商天勤律师事务所（以下简称"本所"）接受重庆智翔金泰生物制 药股份有限公司（以下简称"公司"）的委托，指派律师出席了公司召开的2024 年年度股东大会。根据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司股东会规则》（下称"《股东会规则》"）等法律、法规和规范性文件 以及《重庆智翔金泰生物制药股份有限公司章程》（下称"《公司章程》"）的要 求，就公司 2024 年年度股东大会（下称"本次股东大会"）的相关事宜出具本 法律意见书。 公司已向本所律师提供了本所律师认为出具本法律意见书必要的文件资料， 本所律师对该等文件和资料进行了核查、验证，并据此出具法律意见。 本所律师仅就本次股东大会的召集、召开程序、出席会议人员资格、召集 人资格及会议表决程序、表决结果是否符合《公司法》、《股东会规则》以及 《公司章程》发表意见。 本所律师同意公司将本法律 ...

证券代码：688443 证券简称：智翔金泰 公告编号：2025-026 重庆智翔金泰生物制药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 92 | | --- | --- | | 普通股股东人数 | 92 | | 2、出席会议的股东所持有的表决权数量 | 223,360,127 | | 普通股股东所持有表决权数量 | 223,360,127 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 61.0467 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 61.0467 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 1、 议案名称：《关于公司 2024 年度董事会工作报告的议案》 审议结果：通过 本次股东大会由董事会召集，会议采取现场投票和网络投票相结合的表决方 （一） 股东大会召开 ...

证券代码：688443 证券简称：智翔金泰 公告编号：2025-025 重庆智翔金泰生物制药股份有限公司 首次公开发行战略配售限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发战略配售股份（限售期 24 月）；股票认购方式 为网下，上市股数为2,639,915股。本公司确认，上市流通数量等于该限售期的全 部战略配售股份数量。 本次股票上市流通总数为2,639,915股。 本次股票上市流通日期为2025 年 6 月 20 日。 一、本次限售股上市类型 根据中国证券监督管理委员会《关于同意重庆智翔金泰生物制药股份有限公 司首次公开发行股票注册的批复》（证监许可〔2023〕725 号），重庆智翔金泰生 物制药股份有限公司（以下简称"公司"或"智翔金泰"）首次公开发行人民币 普通股 91,680,000 股，并于 2023 年 6 月 20 日在上海证券交易所科创板挂牌上市。 公司首次公开发行股票完成后，总股本为 366,680,000 股，其中有限售条件流通股 为 283, ...

国泰海通证券股份有限公司 关于重庆智翔金泰生物制药股份有限公司 一、本次限售股上市类型 根据中国证券监督管理委员会《关于同意重庆智翔金泰生物制药股份有限公 司首次公开发行股票注册的批复》（证监许可〔2023〕725 号），重庆智翔金泰生 物制药股份有限公司（以下简称"公司"或"智翔金泰"）首次公开发行人民币普通 股 91,680,000 股，并于 2023 年 6 月 20 日在上海证券交易所科创板挂牌上市。公 司首次公开发行股票完成后，总股本为 366,680,000 股，其中有限售条件流通股 为 283,912,912 股，占本公司发行后总股本的 77.4280%，无限售条件流通股为 82,767,088 股，占本公司发行后总股本的 22.5720%。 首次公开发行战略配售限售股上市流通的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰"或"公司"）首次 公开发行股票并在科创板上市及持续督导的保荐机构，根据《证券发行上市保荐 业务管理办法》《上海证券交易所科创板股票上市规则》等法律法规的相关规定， 对智翔金泰首次公开发行战略 ...

Core Viewpoint - The 2024 Annual General Meeting of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. outlines the procedures and agenda for the meeting, including various proposals for shareholder approval, reflecting the company's operational status and future plans [1][2][3]. Meeting Procedures - Shareholders or their representatives must arrive 30 minutes before the meeting and present identification for attendance verification [2]. - Only authorized personnel, including shareholders, directors, supervisors, and invited guests, are allowed to enter the meeting venue [1][2]. - Shareholders have the right to speak, inquire, and vote during the meeting, with specific rules governing the order and duration of speeches [2][3]. Voting and Proposals - The meeting will utilize both on-site and online voting methods, with specific timeframes for each [4][6]. - Key proposals include the 2024 Board of Directors' work report, the 2024 Supervisory Board's work report, and the 2024 annual financial report, all of which have been approved by the board and supervisory committee [5][8][9]. Financial Performance - The company reported a total asset decrease of 12.49% year-on-year, with total liabilities increasing by 25.83% [21][25]. - The net profit for the year was -79.73 million yuan, a slight improvement from the previous year's loss [21]. - Operating revenue reached 30.10 million yuan, a significant increase of 2384.11% compared to the previous year, primarily due to the launch of the product "Sailiqi Monoclonal Antibody Injection" [21][24]. Expense Analysis - Sales expenses surged by 1030.29% to 117.89 million yuan, attributed to the expansion of the sales team and marketing efforts for the new product [22][23]. - Management expenses decreased by 17.60%, while R&D expenses slightly reduced by 1.71% [22][23]. - Financial expenses showed a significant decrease of 313.63%, mainly due to increased interest income from temporarily idle funds [24]. Future Plans - The company plans to apply for a new comprehensive credit limit of up to 2.5 billion yuan to support its operational goals [12][13]. - Proposals for the 2025 director and supervisor remuneration plans have been outlined, reflecting the company's commitment to aligning compensation with performance [10][12].

股票代码：688443 股票简称：智翔金泰 重庆智翔金泰生物制药股份有限公司 2024 年年度股东大会会议资料 2025 年 6 月 重庆智翔金泰生物制药股份有限公司 2024 年年度股东大会会议资料 目录 | 重庆智翔金泰生物制药股份有限公司 2024 年年度股东大会会议须知 | | 1 | | --- | --- | --- | | 重庆智翔金泰生物制药股份有限公司 2024 年年度股东大会会议议程 | | 3 | | 重庆智翔金泰生物制药股份有限公司 2024 年年度股东大会会议议案 | | 5 | | 议案一：关于公司 年度董事会工作报告的议案 | 2024 | 5 | | 议案二：关于公司《2024 年度监事会工作报告》的议案 | | 6 | | 议案三：关于公司《2024 年年度报告》及其摘要的议案 | | 7 | | 议案四：关于公司《2024 年度财务决算报告》的议案 | | 8 | | 议案五：关于公司 年度利润分配方案的议案 | 2024 | 9 | | 议案六：关于续聘公司 年度审计机构的议案 | 2025 | 10 | | 议案七：关于公司 年度董事薪酬方案的议案 11 | 2025 ...